Enzon Pharmaceuticals Inc
Enzon Pharmaceuticals, Inc. does not have significant operations. Previously, it was engaged in the sale of its patented drug product, PegIntron. The company was formerly known as Enzon, Inc and changed its name to Enzon Pharmaceuticals, Inc. in December 2002. Enzon Pharmaceuticals, Inc. was incorporated in 1981 and is headquartered in Cranford, New Jersey.
Enzon Pharmaceuticals Inc (ENZN) - Total Liabilities
Latest total liabilities as of September 2025: $44.62 Million USD
Based on the latest financial reports, Enzon Pharmaceuticals Inc (ENZN) has total liabilities worth $44.62 Million USD as of September 2025.
Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities.
Enzon Pharmaceuticals Inc - Total Liabilities Trend (1999–2024)
This chart illustrates how Enzon Pharmaceuticals Inc's total liabilities have evolved over time, based on quarterly financial data. Explore and compare other companies by total liabilities.
Enzon Pharmaceuticals Inc Competitors by Total Liabilities
The table below lists competitors of Enzon Pharmaceuticals Inc ranked by their total liabilities.
| Company | Country | Total Liabilities |
|---|---|---|
|
Mehadrin
TA:MEDN
|
Israel | ILA734.74 Million |
|
Qualigen Therapeutics Inc
NASDAQ:QLGN
|
USA | $4.92 Million |
|
Tempest Minerals Ltd
AU:TEM
|
Australia | AU$391.09K |
|
Polyram Plastic Industries Ltd
TA:POLP
|
Israel | ILA543.64 Million |
|
One World Lithium Inc
OTCQB:OWRDF
|
USA | $2.99 Million |
Liability Composition Analysis (1999–2024)
This chart breaks down Enzon Pharmaceuticals Inc's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted.
Liquidity & Leverage Metrics
Key Metrics Explained
| Metric | Value | Description |
|---|---|---|
| Current Ratio | 80.86 | Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities) |
| Quick Ratio | N/A | More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities) |
| Cash Ratio | N/A | Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities) |
| Debt to Equity | -48.34 | Measures financial leverage (Total Liabilities ÷ Shareholder Equity) |
| Debt to Assets | 1.02 | Portion of assets financed with debt (Total Liabilities ÷ Total Assets) |
Liability Trends Comparison
This chart compares key liability metrics across different time periods, showing how Enzon Pharmaceuticals Inc's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.
Annual Total Liabilities for Enzon Pharmaceuticals Inc (1999–2024)
The table below shows the annual total liabilities of Enzon Pharmaceuticals Inc from 1999 to 2024.
| Year | Total Liabilities | Change |
|---|---|---|
| 2024-12-31 | $44.16 Million | -0.08% |
| 2023-12-31 | $44.20 Million | +2501.35% |
| 2022-12-31 | $1.70 Million | -96.04% |
| 2021-12-31 | $42.89 Million | +10309.22% |
| 2020-12-31 | $412.00K | -2.60% |
| 2019-12-31 | $423.00K | -18.18% |
| 2018-12-31 | $517.00K | +40.49% |
| 2017-12-31 | $368.00K | -60.85% |
| 2016-12-31 | $940.00K | -80.42% |
| 2015-12-31 | $4.80 Million | -11.70% |
| 2014-12-31 | $5.44 Million | +191.37% |
| 2013-12-31 | $1.87 Million | -98.47% |
| 2012-12-31 | $122.31 Million | -16.24% |
| 2011-12-31 | $146.03 Million | -6.99% |
| 2010-12-31 | $157.00 Million | -43.82% |
| 2009-12-31 | $279.47 Million | -9.14% |
| 2008-12-31 | $307.59 Million | -19.85% |
| 2007-12-31 | $383.78 Million | -16.62% |
| 2006-12-31 | $460.27 Million | +2.89% |
| 2004-12-31 | $447.36 Million | +3.24% |
| 2003-12-31 | $433.32 Million | -0.84% |
| 2002-12-31 | $436.98 Million | +3.98% |
| 2001-12-31 | $420.25 Million | +2.33% |
| 2000-12-31 | $410.69 Million | +4320.74% |
| 1999-12-31 | $9.29 Million | -- |